Epcoritamab and Rituximab for First-line Follicular Lymphoma
Status:
Not yet recruiting
Trial end date:
2029-02-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how effective and safe the combination of rituximab
and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not
received other treatments for their lymphoma.
The names of the study drugs involved in this study are:
- Rituximab (a type of monoclonal antibody therapy)
- Epcoritamab (a T-cell bispecific antibody)